Biomarin Pharmaceutical (BMRN) Other Accumulated Expenses (2010 - 2019)

Biomarin Pharmaceutical (BMRN) has 10 years of Other Accumulated Expenses data on file, last reported at $19.2 million in Q1 2019.

• Quarterly Other Accumulated Expenses rose 16.53% year-over-year to $19.2 million in Q1 2019, while the trailing twelve-month figure through Mar 2019 was $19.2 million (up 16.53% YoY) and the FY2018 annual result came in at $20.0 million, up 6.15% from the prior year.
• Other Accumulated Expenses declined to $19.2 million in Q1 2019, from $20.0 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $20.0 million in Q4 2018 to a low of $7.2 million in Q1 2015.
• A 5-year average of $14.7 million and a median of $15.2 million in 2016 frame the typical range for Other Accumulated Expenses.
• Annual changes were most pronounced in 2015 — Other Accumulated Expenses jumped 88.57% — and 2017, when it advanced 5.7%.
• Tracing BMRN's Other Accumulated Expenses over 5 years: stood at $10.4 million in 2015, then soared by 45.51% to $15.2 million in 2016, then rose by 24.22% to $18.8 million in 2017, then climbed by 6.15% to $20.0 million in 2018, then retreated by 3.77% to $19.2 million in 2019.
• The last three Other Accumulated Expenses figures came in at $19.2 million (Q1 2019), $20.0 million (Q4 2018), and $19.3 million (Q3 2018), per Business Quant data.